Christina M. Annunziata

Is there a genomic basis for primary chemoresistance in ovarian cancer?

Proteomics in clinical trials and practice: present uses and future promise.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer.

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Uterine papillary serous carcinoma: a new paradigm for treatment?

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.

Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.

CD157 in ovarian carcinoma: how does it help us?

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

IKK-ε coordinates invasion and metastasis of ovarian cancer.

Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.

Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.

Novel facts about FAK: new connections to drug resistance?

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells.

Loss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.